Angelini fortifies neurology portfolio with $4.1B buyout of Catalyst Pharma

Summary

Angelini Pharma is acquiring Catalyst Pharmaceuticals for $4.1 billion to gain three FDA-approved treatments for rare neurological diseases, including Firdapse for Lambert-Eaton myasthenic syndrome.